CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cyclin-dependent kinase 7 (CDK7) plays a role in cancer cell proliferation.
• Existing CDK7 inhibitors have off-target effects, complicating mechanism elucidation.
• Understanding CDK7's role in multiple myeloma (MM) is crucial for targeted therapy development.

Purpose of the Study:

• To investigate the precise mechanisms by which CDK7 inhibition affects multiple myeloma (MM) cells.
• To evaluate the therapeutic potential of selective CDK7 inhibition in MM models.

Main Methods:

• Correlation analysis of CDK7 expression with E2F and MYC transcriptional programs in MM patient cells.
• Selective targeting of CDK7 using the covalent inhibitor YKL-5-124.
• Assessment of E2F activity, MYC-regulated metabolic genes, glycolysis, and lactate production in MM cells.
• In vivo studies using mouse models of MM, including a MYC-dependent model.

Main Results:

• CDK7 expression positively correlates with E2F and MYC activity in MM cells.
• Selective CDK7 inhibition counteracts E2F activity and impairs MYC-driven metabolic gene expression, leading to reduced glycolysis and lactate production.
• YKL-5-124 treatment resulted in significant tumor regression and increased survival in MM mouse models.
• Minimal effects were observed in normal cells, indicating therapeutic selectivity.

Conclusions:

• CDK7 is a master regulator of oncogenic programs essential for MM growth and survival.
• Selective CDK7 inhibition, particularly with YKL-5-124, offers a promising therapeutic strategy for multiple myeloma.
• YKL-5-124 demonstrates potential for clinical development in MM treatment due to its efficacy and selectivity.